CD37 and B-cell chronic lymphocytic leukemia: Stilgenbauer et al. has reported human experience with anti-CD37 antibody in CLL, and indicated that it was a valid treatment with acceptable tolerability and notable efficacy, especially in difficult-to-treat patients with poor-risk features including del(17p) or TP53 mutations [31].